Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response (NCT06641089)
A Phase 3, Parallel-group, Randomized, Double-blind, 4-arm, Placebo-controlled, Multicenter Study With Risankizumab as Active Reference Arm, to Investigate the Efficacy and Safety of Subcutaneous Sonelokimab in Male and Female Participants Aged 18 Years and Over With Active Psoriatic Arthritis and Previous Inadequate Response or Intolerance to Tumor Necrosis Factor-α Inhibitors
🩺 Plain-English Summary (8th-Grade Level)
This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor necrosis factor (TNF)α therapy.
Who can join: Review the eligibility criteria below.
Location: Clinical Site — Avondale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (142 Sites)
Showing the first 25 of 142 sites.
- Clinical Site — Avondale, Arizona
- Clinical Site — Chandler, Arizona
- Clinical Site — Flagstaff, Arizona
- Clinical Site — Mesa, Arizona
- Clinical Site — Phoenix, Arizona
- Clinical Site — Scottsdale, Arizona
- Clinical Site — Tucson, Arizona
- Clinical Site — Jonesboro, Arkansas
- Clinical Site — La Jolla, California
- Clinical Site — Pomona, California
- Clinical Site — San Diego, California
- Clinical Site — Santa Monica, California
- Clinical Site — Thousand Oaks, California
- Clinical Site — Upland, California
- Clinical Site — Avon Park, Florida
- Clinical Site — Clearwater, Florida
- Clinical Site — Hialeah, Florida
- Clinical Site — Miami Gardens, Florida
- Clinical Site — Tampa, Florida
- Clinical Site — Zephyrhills, Florida
- Clinical Site — Gainesville, Georgia
- Clinical Site — Springfield, Illinois
- Clinical Site — Lake Charles, Louisiana
- Clinical Site — Baltimore, Maryland
- Clinical Site — Grand Blanc, Michigan
📞 Contact the Study Coordinator
Phone: +41 41 510 8022
Email: ClinicalTrials@moonlaketx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Arthritis, Psoriatic
- A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice — Buenos Aires,
- Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug — Avondale, Arizona
- A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis — Jonesboro, Arkansas
- A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease — Avondale, Arizona
- A Study of Guselkumab in Participants With Active Psoriatic Arthritis — Birmingham, Alabama
- A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis — Glendale, Arizona
Explore by condition: All Arthritis, Psoriatic clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.